Zinger Key Points
- Ayurcann's net revenue leaps to CA$6.5M in Q1 2024, a strong rise from last year's figures.
- Earnings reveal a staggering 249% increase in gross revenue, hitting CA$11.8 million.
- The company makes a significant foray into the booming infused pre-roll market, tapping into a fast-growing consumer trend.
- China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley. Get the next trade alert free.
Ayurcann Holdings Corp AYURF, a leading Canadian cannabis extraction company, announced its financial and operational results on Wednesday for the three months ended September 30, 2023.
Q1 2024 Financial Highlights
- Net revenue was CA$6.5 million (US $4.8 million) for the three months ended September 30, 2023. This represents a significant increase compared to the CA$2 million reported for the same period in 2022.
- Net loss reported was CA$180 thousand, a strong decrease compared to the CA$968,000 from the same period last year.
- Adjusted EBITDA was not included in the earnings report.
- Gross profit reported CA$2.3 million, also showing a strong uptick in comparison to the CA$366,000 from the same period last year.
The company, specializing in derivative cannabis 2.0 and 3.0 products in the recreational cannabis market, reported a significant 249% increase in gross revenue, reaching CA$11.9 million ($8.7 million) in Q1 2024, a substantial rise from CA$3.6 million ($2.5 million) in the previous year.
Alongside this revenue growth, Ayurcann maintained a gross margin of 35%, reflecting their operational efficiency and market impact. Additionally, the company's cash reserves have improved, with cash on hand totaling CA$1.5 million at the end of the period, compared to CA$1 million last year.
Entering the rapidly expanding infused pre-roll sector, Ayurcann aligns with market trends where pre-rolls, particularly infused ones, have seen exponential growth in both the U.S. and Canada.
CEO's Outlook
"We feel that the awareness of our brands in the market and the quality and flavor profile we are introducing will enable Ayurcann to gain market share quickly. Offering value and potency in a segment that is primed to grow even more," said Igal Sudman, CEO.
AYURF Price Action
AYURF's shares were trading at $0.015 per share, the same as yesterday's closing price, at the time of this writing around noon ET Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!